Abraxane for Injectable Suspension 100mg

Manufacturer
BAXTER ONCOLOGY GMBH(GERMANY)

Registraction Number
MAL14125061ACRZ

Content:
Abraxane for Injectable Suspension 100mg contains paclitaxel as the active ingredient. It is a microtubule inhibitor used in cancer treatment.
Indications:
Abraxane is indicated for the treatment of:

1. Metastatic Breast Cancer: After failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
2. Non-Small Cell Lung Cancer (NSCLC): As first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
3. Metastatic Adenocarcinoma of the Pancreas: As first-line treatment in combination with gemcitabine.

• Metastatic Breast Cancer: Recommended dosage is 260 mg/m² intravenously over 30 minutes every 3 weeks.
• Non-Small Cell Lung Cancer: Recommended dosage is 100 mg/m² intravenously over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; carboplatin is administered on Day 1 of each cycle immediately after Abraxane.
• Metastatic Adenocarcinoma of the Pancreas: Recommended dosage is 125 mg/m² intravenously over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; gemcitabine is administered on Days 1, 8, and 15 of each cycle immediately after Abraxane.